Prostate cancer (PCa) is the most common male malignancy in many Western countries. Primary PCa is hormone dependent and is manageable by hormonal therapy. However, it rapidly develops to hormone-refractory tumors due to the accumulation of mutations in the androgen receptor and/or the acquisition of alternative cellular pathways that support proliferation and inhibit apoptosis of prostate canc...

Introduction: Keratoconus is an ectasia that results in corneal thinning in central and paracentral areas of affected corneas. This disease occurs most frequently in young males, underlying a potential role of sex hormones in its pathogenesis. By examining the expression of sex hormone receptors, this study aimed to reveal potential roles of the sex hormone receptors in keratoconus pathogenesis...

OBJECTIVES Our aim was to examine how certain signal transduction pathways influence the regulation of hormone-dependent kallikrein (KLK) gene expression in androgen-sensitive breast cancer cell lines. METHODS We used the breast cancer cell lines T47D and BT474, treated with steroid hormones or various pathway inhibitors. KLKs were quantified by ELISA. RT-PCR, Western blots and immunoprecipit...

Apalutamide is a non-steroidal selective androgen receptor inhibitor approved for the treatment of high-risk non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive cancer. The paper describes case patient diagnosed with long-term course disease. was stage 18 years after primary treatment. Systemic apalutamide recommended. Initially, carried out as part extended acc...

Hormonal manipulation plays a significant role in the treatment of advanced hormone naïve prostate cancer and castration-resistant prostate cancer (CRPC) with or without previous chemotherapy. Combination of gonadotropin releasing hormone (GnRH) agonists and androgen receptor (AR) antagonists (combined androgen blockade; CAB) is the first line therapy for advanced hormone naïve prostate cancer,...

Overexpression of TOP2A is associated with risk of systemic progression in prostate cancer patients, and higher levels of TOP2A were found in hormone-resistant cases. To elucidate the mechanism by which high levels of TOP2A contribute to tumor progression we generated TOP2A overexpressing prostate cancer cell lines. We show that TOP2A promotes tumor aggressiveness by inducing chromosomal rearra...

The male hormone androgen, working through the androgen receptor (AR), plays a major role in physiological process and disease development. Previous studies of AR mainly focus on its transcriptional activity. Here, we found that androgen-induced TMPRSS2 and ERG gene proximity is mediated by AR control of DNA replication rather than gene transcription. We demonstrate that, in both AR transactiva...

Hormonal treatment of advanced prostate cancer should be considered for patients who have stages C and D1 disease, a high risk of recurrence after local therapy, or prostate-specific antigen-measured recurrence after local treatment. This approach is dependent on most prostate cancer cells being androgen-dependent, but androgen-independent cells may arise after several years of hormonal therapy...

Introduction and purpose: Prostate cancer (PCa) as one of the most frequent neoplasms in men remains a challenge for oncologists. The main strategy its treatment is Androgen Deprivation Therapy (ADT) principle which an inducement hypogonadism. lack testosterone not only factor greatly contributing to decrease quality life overall, but additionally it increases odds complications, including low ...

The report by Huggins and Hodges in 1941’ that endocrine manipulation caused a decrease in acid phosphatase dramatically changed the treatment of metastatic prostatic cancer. Since that time, case reports have clearly described objective responses to hormonal manipulation of this disease.2.3 Nevertheless, although it is generally accepted that hormonal therapy produces subjective remissions in ...